Zobrazeno 1 - 10 of 26 pro vyhledávání: '"Thierry, Lafont"'
1
Akademický článek
Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
Autor: Maud Maillard, Cécile Arellano, Christelle Vachoux, Christine Chevreau, Nicolas J. Cabaton, Frédéric Pont, Nathalie Saint-Laurent, Thierry Lafont, Etienne Chatelut, Fabienne Thomas
Publikováno v: Metabolites, Vol 12, Iss 9, p 852 (2022)
Tyrosine kinase inhibitors pazopanib and sunitinib are both used to treat advanced renal cell carcinoma but expose patients to an increased risk of hepatotoxicity. We have previously identified two aldehyde derivatives for pazopanib and sunitinib (P-
Externí odkaz: https://doaj.org/article/23cee1aa9b5b4384baac2abc171b2232
Zobrazit plný text záznamu
3
Body Surface Area Dosing of High-Dose Methotrexate Should be Reconsidered, Particularly in Overweight, Adult Patients
Autor: Etienne Chatelut, Lucie Oberic, Thierry Lafont, Fanny Gallais, Stanislas Faguer, Florent Puisset, Aurélie Brice, Sabrina Marsili, Suzanne Tavitian
Publikováno v: Therapeutic Drug Monitoring.
Background High-dose methotrexate is used for treating several types of cancer. However, it is associated with a high risk of acute kidney injury (AKI), especially in patients with high MTX concentrations. Although therapeutic drug monitoring is perf
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7a55d7b25fac7e67ab24e719eb041ee
https://doi.org/10.1097/ftd.0000000000000813
Zobrazit plný text záznamu
4
Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report
Autor: Fabienne Thomas, Gareth J. Veal, Nicolas Picard, Laurence Brugières, Etienne Chatelut, Souleiman El Balkhi, Christophe Piguet, Thierry Lafont
Publikováno v: Cancer Chemotherapy and Pharmacology. 82:361-365
Chemotherapy dosing in neonates represents a major clinical challenge because of a lack of clinical pharmacology information in this patient population. In this study, we investigate the use of cisplatin dose adaptation based on therapeutic drug moni
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4557ecbf1b66b9520f98b1e7aa103743
https://doi.org/10.1007/s00280-018-3625-5
Zobrazit plný text záznamu
5
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients
Autor: Françoise Perriard, Thierry Lafont, Karine Aubry, Ben Allal, Joël Guigay, Catherine Alix-Panabières, Marc Alfonsi, Félicien Le Louedec, Martine Mazel, Etienne Chatelut, L. Digue, Didier Cupissol, Fabienne Thomas, François Becher, Benjamin Lallemant, Jean-Pierre Delord, Renaud Garrel
Publikováno v: British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, Wiley, 2019, 85 (6), pp.1357-1366. ⟨10.1111/bcp.13907⟩
British Journal of Clinical Pharmacology, 2019, 85 (6), pp.1357-1366. ⟨10.1111/bcp.13907⟩
Br J Clin Pharmacol
International audience; Aims Cetuximab associated with cisplatin and 5-fluorouracil is used to treat patients with inoperable or metastatic head and neck squamous cell carcinomas (HNSCC) up until disease progression or unacceptable toxicities. To dat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11287ab319e4af6d10a937f136b50504
https://hal.inrae.fr/hal-02620695
Zobrazit plný text záznamu
6
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid
Autor: Etienne Chatelut, Ben Allal, Thierry Lafont, Cécile Danel, Pascal Odou, David Beauvais, Eileen M Boyle, Jean-François Goossens, Stéphanie Genay, Franck Morschhauser, Charles Herbaux
Publikováno v: Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences
Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, Elsevier, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1093-1094, pp.158-166. ⟨10.1016/j.jchromb.2018.06.026⟩
Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, Elsevier, 2018, 1093-1094, pp.158-166. ⟨10.1016/j.jchromb.2018.06.026⟩
Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1093-1094, pp.158-166. ⟨10.1016/j.jchromb.2018.06.026⟩
International audience; Ibrutinib is an orally administered first-in-class irreversible Bruton's tyrosine kinase (BTK) covalent inhibitor for the treatment of patients with B-cell malignancies. Several isolated clinical observations reported its effi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8be3e6d114b36e3feb8ef7a6180dc6c4
https://hal.univ-lille.fr/hal-02178925
Zobrazit plný text záznamu
7
Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site
Autor: Fabienne Thomas, Etienne Chatelut, Marie-Noëlle Paludetto, Melanie White-Koning, Helen Powell, Thierry Lafont, Sylvie Negrier, Diane-Charlotte Imbs
Publikováno v: Investigational New Drugs. 34:41-48
Introduction Pazopanib exhibits wide inter-patient pharmacokinetic variability which may contribute to differences in treatment outcome. Unbound drug concentrations are believed to be more relevant to pharmacological responses than total concentratio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90b17c2d8c29033dcd30f2d59e4989c2
https://doi.org/10.1007/s10637-015-0304-9
Zobrazit plný text záznamu
8
Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS
Autor: Cécile Arellano, Etienne Chatelut, Florent Puisset, Marie-Noëlle Paludetto, Félicien Le Louedec, Ben Allal, Thierry Lafont
Publikováno v: Journal of pharmaceutical and biomedical analysis. 154
Pazopanib is a multi-targeted tyrosine kinase inhibitor (TKI) approved as first-line treatment for patients with advanced renal cell carcinoma (RCC) and as second-line treatment for patients with advanced soft tissue sarcoma (STS) previously treated
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::072fa1b00f84ce5cae0a1f35daa369bd
https://pubmed.ncbi.nlm.nih.gov/29571135
Zobrazit plný text záznamu
9
Pharmacokinetics of pazopanib administered in combination with bevacizumab
Autor: Andrea Varga, Thierry Lafont, Etienne Chatelut, Bernard Escudier, Antoine Hollebecque, Jean-Charles Soria, David Pérol, Diane-Charlotte Imbs, Ellen Blanc, Sylvie Negrier, Philippe A. Cassier
Publikováno v: Cancer Chemotherapy and Pharmacology. 73:1189-1196
A combination of monoclonal antibody that binds and inhibits effects induced by vascular endothelial growth factor and tyrosine kinase inhibitor of vascular endothelial growth factor receptor represents a promising concept to block pathological angio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dce2e902fa73c20b8c039e0e33c2154d
https://doi.org/10.1007/s00280-014-2455-3
Zobrazit plný text záznamu
10
Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease
Autor: Anaïs Grand, Chantal Le Guellec, Thierry Lafont, Florent Puisset, Frédérique Haberer, Hélène Blasco, Etienne Chatelut, Melanie White-Koning, Nassim Kamar, Lionel Rostaing, Antoine Huart, Jacques Pourrat
Publikováno v: British Journal of Clinical Pharmacology. 76:734-740
Aims Both rituximab and plasmapheresis can be associated in the treatment of immune-mediated kidney diseases. The real impact of plasmapheresis on rituximab pharmacokinetics is unknown. The aim of this study was to compare rituximab pharmacokinetics
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf90cf44414a7dc08bd46c570539d9ae
https://doi.org/10.1111/bcp.12098
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje